Cyclo-oxygenase-2 inhibition and exacerbation of myocardial dysfunction--protection with nitric oxide?
Letts
Gordon
G
NitroMed Inc., 12 Oak Drive, Bedford, Massachusetts, MA 01730, USA. Gletts@Nitromed.com
D000818:Animals; D009202:Cardiomyopathies / Q000201:enzymology* / Q000503:physiopathology* / Q000517:prevention & control; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects / Q000494:pharmacology*; D006801:Humans; D007527:Isoenzymes / Q000037:antagonists & inhibitors* / Q000378:metabolism; D008565:Membrane Proteins; D009569:Nitric Oxide / Q000502:physiology*; D011451:Prostaglandin-Endoperoxide Synthases / Q000378:metabolism
D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D007527:Isoenzymes; D008565:Membrane Proteins; D009569:Nitric Oxide; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases